We have revised our NII estimates by 0.4%/0.4%, PPOP estimates by 1.2%/0.4% and PAT estimates by -0.3%/2.3% for FY20/FY21, respectively. We have retained Buy rating on SBL, revising our target price on it to Rs15 (from Rs15 earlier) and valuing the stock at 0.5x FY21E P/BV.
With the banks focus on improving retail mix, we expect the asset quality to improve going forward. However, we are bit cautious on an increase in SMA2 accounts and we don’t expect a considerable decline in cost of funds in near to medium term. Hence, we reduce our valuation to 0.45x BV of FY21E (from previous 0.5x) with a revised downward target price of Rs13.9 and downgrade our rating to Hold.
SIB’s earnings were marginally below expectations with PAT at Rs733mn(PLe: Rs890mn) as operating performance is improving only gradually. Provisions came in lower as slippages of Rs2.41bn was lower sequentially which helped stable asset quality but marginally lift PCR to 32.3% (45.1% incl. technical w.off). Bank is closely monitoring some of the dispensation related loans restructured during Kerala floods but does not see large risks from same. Structurally PCR remains lowest in peer group which has to be stepped up, which should be helped by improving operations. We maintain BUY with TP of Rs18 (unchanged) based on 0.8x Mar-21 ABV.